Cellectis - ADR
NASDAQ:CLLS 3:59:56 PM EDT
| Market Cap (Intraday) | 703.31M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $15.09 |
| 50-Day MA | $16.29 |
| 200-Day MA | $21.19 |
Cellectis - ADR Stock, NASDAQ:CLLS
8, rue de la Croix Jarry, Paris, Ile-de-France 75013
France
Phone: +33.1.81.69.16.00
Number of Employees: 281
Description
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and Andr�© Choulika on February 20, 1999 and is headquartered in Paris, France.